Anjan Thakurta
Overview
Explore the profile of Anjan Thakurta including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
2247
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Amatangelo M, Flynt E, Stong N, Ray P, Van Oekelen O, Wang M, et al.
Cell Rep Med
. 2024 May;
5(6):101571.
PMID: 38776914
Iberdomide is a next-generation cereblon (CRBN)-modulating agent in the clinical development in multiple myeloma (MM). The analysis of biomarker samples from relapsed/refractory patients enrolled in CC-220-MM-001 (ClinicalTrials.gov: NCT02773030), a phase...
2.
Van Oekelen O, Amatangelo M, Guo M, Upadhyaya B, Cribbs A, Kelly G, et al.
Cell Rep Med
. 2024 May;
5(6):101584.
PMID: 38776911
Iberdomide is a potent cereblon E3 ligase modulator (CELMoD agent) with promising efficacy and safety as a monotherapy or in combination with other therapies in patients with relapsed/refractory multiple myeloma...
3.
Prabhala R, Pierceall W, Samur M, Potluri L, Hong K, Peluso T, et al.
Front Oncol
. 2023 Dec;
13:1271807.
PMID: 38111533
Background: Multiple Myeloma (MM) patients exhibit dysregulated immune system, which is further weakened by chemotherapeutic agents. While cereblon-modulating agents, such as pomalidomide and lenalidomide, have been found to improve the...
4.
Neri P, Barwick B, Jung D, Patton J, Maity R, Tagoug I, et al.
Blood Cancer Discov
. 2023 Nov;
5(1):56-73.
PMID: 37934799
Significance: We show that IKZF1-bound enhancers are critical for IMiD efficacy and that the factor ETV4 can bind the same enhancers and substitute for IKZF1 and mediate IMiD resistance by...
5.
Mitchell J, Khan D, Rana R, Kriek N, Unsworth A, Sage T, et al.
Platelets
. 2023 Oct;
34(1):2264940.
PMID: 37822056
Multiple myeloma (MM) and its precursor states, smoldering myeloma (SM) and monoclonal gammopathy of undetermined significance (MGUS) are associated with increased incidence of thrombosis, however the cause of this is...
6.
Garbowski M, Ugidos M, Risueno A, Shetty J, Schwickart M, Hermine O, et al.
Am J Hematol
. 2023 Oct;
99(2):182-192.
PMID: 37782758
Luspatercept, a ligand-trapping fusion protein, binds select TGF-β superfamily ligands implicated in thalassemic erythropoiesis, promoting late-stage erythroid maturation. Luspatercept reduced transfusion burden in the BELIEVE trial (NCT02604433) of 336 adults...
7.
Menezes D, See W, Risueno A, Tsai K, Lee J, Ma J, et al.
Br J Haematol
. 2023 Mar;
201(6):1129-1143.
PMID: 36990798
Oral azacitidine (Oral-AZA) maintenance therapy improved relapse-free (RFS) and overall survival (OS) significantly versus placebo for AML patients in remission after intensive chemotherapy (IC) in the phase 3 QUAZAR AML-001...
8.
Kurata K, James-Bott A, Tye M, Yamamoto L, Samur M, Tai Y, et al.
Blood Cancer J
. 2023 Feb;
13(1):24.
PMID: 36746923
No abstract available.
9.
Kurata K, James-Bott A, Tye M, Yamamoto L, Samur M, Tai Y, et al.
Blood Cancer J
. 2023 Jan;
13(1):12.
PMID: 36631435
Multiple myeloma (MM) is a plasma cell malignancy characterised by aberrant production of immunoglobulins requiring survival mechanisms to adapt to proteotoxic stress. We here show that glutamyl-prolyl-tRNA synthetase (GluProRS) inhibition...
10.
Samur M, Roncador M, Aktas Samur A, Fulciniti M, Bazarbachi A, Szalat R, et al.
Blood
. 2023 Jan;
141(14):1724-1736.
PMID: 36603186
High-dose melphalan (HDM) improves progression-free survival in multiple myeloma (MM), yet melphalan is a DNA-damaging alkylating agent; therefore, we assessed its mutational effect on surviving myeloma cells by analyzing paired...